Who is sponsoring NCT05034770?

NCT05034770 is sponsored by Emine Dundar Ahi, MD.

What drugs are being tested in NCT05034770?

Interventions in NCT05034770: major ozone autohemotherapy.

What condition does NCT05034770 study?

NCT05034770 studies Fibromyalgia Syndrome.

Is NCT05034770 still recruiting?

NCT05034770 is currently completed. Last updated 5 August 2022.

Last reviewed 2022-08-05 · How we verify

NCT05034770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Major Ozone Autohemotherapy in the Treatment of Fibromyalgia Syndrome

Completed Last updated 5 August 2022

What this trial tests

trial testing major ozone autohemotherapy in Fibromyalgia Syndrome in 45 participants. Completed in 11 January 2022.

Timeline

1 January 2017

Primary endpoint
10 January 2022

11 January 2022

Quick facts

Lead sponsor	Emine Dundar Ahi, MD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	45
Start date	1 January 2017
Primary completion	10 January 2022
Estimated completion	11 January 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

major ozone autohemotherapy

Conditions studied

Fibromyalgia Syndrome — all drugs for Fibromyalgia Syndrome →

Sponsor

Emine Dundar Ahi, MD

Who can join

Adults 18 to 60, any sex, with Fibromyalgia Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients who were admitted to the Physical Medicine and Rehabilitation (PMR) outpatient clinic of our hospital between January 2017 and December 2020 and were treated with Major ozone autohemotherapy with a diagnosis of Fibromyalgia syndrome will include to the study. Visual anolog scale (VAS), Fibromyalgia Impact Questionnare (FIQ) and Short Form Health Survey-36 (SF-36) scores of the patients before and after treatment were recorded. Statistical analysis of these outcome scores will be made.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fibromyalgia Syndrome

Currently open trials in the same condition.

NCT07327775 — Fibromyalgia Disease Burden in Mothers of Children With Attention-Deficit/Hyperactivity Disorder · recruiting
NCT06929598 — Shiatsu for Chronic Non-Inflammatory Pain in Children and Adolescents · NA · recruiting
NCT06957873 — Craniovertebral Angle and Fibromyalgia Severity · recruiting
NCT06539793 — Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome · NA · recruiting
NCT05900466 — Metformin for Fibromyalgia Symptoms (INFORM Trial) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05034770 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emine Dundar Ahi, MD
Last refreshed: 5 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05034770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing